Nanobiotix (NASDAQ:NBTX) Announces Quarterly Earnings Results

Nanobiotix (NASDAQ:NBTX) announced its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.43), FiscalAI reports. The firm had revenue of $3.42 million during the quarter, compared to analyst estimates of $41.95 million.

Nanobiotix Stock Up 0.9%

NBTX stock traded up $0.29 on Tuesday, hitting $30.87. 69,166 shares of the company’s stock were exchanged, compared to its average volume of 44,906. The firm has a 50 day moving average price of $27.43 and a two-hundred day moving average price of $22.97. Nanobiotix has a 12-month low of $2.99 and a 12-month high of $41.89.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. Finally, Guggenheim raised their price target on shares of Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 6th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Nanobiotix has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Institutional Investors Weigh In On Nanobiotix

Several institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC purchased a new stake in shares of Nanobiotix during the fourth quarter worth about $390,000. Marshall Wace LLP purchased a new position in shares of Nanobiotix in the 4th quarter valued at approximately $220,000. Finally, Royal Bank of Canada raised its position in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the last quarter. Institutional investors and hedge funds own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.